Perry CJ, Finch P, Muller-Taubenberger A, Leung KY, Warren EC, Damstra-Oddy J, Sharma D, Patra PH, Glyn S, Boberska J, Stewart B, Baldwin A, Piscitelli F, Harvey RJ, Harwood A, Thompson C, Claus SP, Greene NDE, McNeish AJ, Williams CM, Whalley BJ and Williams RSB

Br J Pharmacol (2020) 177: 912-928

Link to abstract

Epidiolex™, a form of highly purified cannabidiol (CBD) derived from Cannabis plants, has demonstrated seizure control activity in patients with Dravet syndrome, without a fully elucidated mechanism of action. We have employed an unbiased approach to investigate this mechanism at a cellular level.